Guia de aquisição de centrífugas industriais 2026: Tipos de produtos, especificações, padrões e seleção de fornecedores
Industrial Centrifuge Procurement Guide 2026: Product Types, Specifications, Standards and Supplier Selection
A procurement-screening framework for chemical and pharmaceutical solid-liquid separation applications, covering type selection, European safety screening and supplier qualification inputs.
Executive Summary
This report addresses the following procurement question: which industrial centrifuge product paths best fit chemical and pharmaceutical requirements in the 2025–2026 selection window when assessed through separation configuration, application evidence and European safety screening? Its central conclusion is that a generic “industrial centrifuge” request is too broad to support supplier qualification. The available evidence supports an initial route based on separation mechanism, process function, application setting and scale stage, followed by model-specific technical validation.
Global product evidence shows a meaningful structural distinction. Sedimentation centrifuges represented 56.6% of the reported industrial centrifuge category in 2025, while filtering centrifuges carry a reported annual growth outlook of 7.2%. The filtering growth signal is associated with API crystallization and specialty-chemical purification. In pharmaceutical manufacturing, horizontal scraper centrifuges show a reported adoption level of approximately 57%, making scraper-related configurations a relevant screening path rather than a universal pharmaceutical default.
Company-reported product information further indicates that chemical and pharmaceutical applications can be associated with vertical filtering, decanting and filtration centrifuges, and can span separation, filtration, clarification and drying from laboratory development through full-scale production. This combination does not establish equivalent performance among designs. It does establish the procurement need to qualify a supplier against a defined process duty, discharge requirement and scale-stage requirement instead of accepting a generic application claim.
For equipment intended for European use, EN 12547:2014 is the verified safety-standard reference for centrifuges, with household and laboratory models outside its scope under the stated laboratory standard boundary. Buyers should request an evidence package mapped to this industrial equipment scope before treating European deployment as qualified.
The report is global in market context, limited to chemical, fine-chemical and pharmaceutical separation applications, and is designed for strategic sourcing teams at supplier-qualification stage. It does not benchmark prices, lead times, throughput, materials, automation, cleanability, certifications or supplier rankings because verified model-level evidence was not available.
Research Scope & Methodology
The product scope covers industrial sedimentation, filtering, horizontal scraper, vertical filtering and decanting centrifuge configurations used in chemical, fine-chemical and pharmaceutical separation processes. The analysis uses 2025–2026 market and product-selection evidence, while retaining EN 12547:2014 as the verified European safety reference.
“Configuration” in this report means the equipment path named in the available evidence; it does not mean that all configurations are technically interchangeable. “Application relevance” means an observed market association or a company-reported product-and-application statement. It is not independent validation of capacity, process performance, certification, hygiene, hazardous-area suitability, export capability or service coverage.
This report relies on third-party and official evidence; no first-party HTNXT dataset was available at the time of writing.
The method applies a procurement classification rather than a supplier ranking: first identify the separation mechanism and required process function; then identify the relevant application context and scale stage; then request supplier documentation; and finally apply European safety screening where market access is relevant. Company statements are used only as qualitative inputs for screening questions. They are not used to rank suppliers or validate technical performance.
Key Findings
Finding One — The larger current product share and the stronger filtering growth signal point to different procurement roles.
Verified Evidence. Sedimentation centrifuges held 56.6% of the reported global industrial centrifuge market in 2025. Filtering centrifuges are forecast to grow at 7.2% annually. The broader category is also projected to grow at 6.3% annually through 2030.
HTNXT Analysis. The reported filtering growth rate is 0.9 percentage points above the reported overall category rate. This is an HTNXT calculation using the two reported annual growth rates: 7.2% minus 6.3% equals 0.9 percentage points. The result should not be read as a market-share forecast. It indicates that category scale and category momentum are not the same procurement signal: sedimentation has the larger reported current footprint, whereas filtering deserves specific examination where a buyer’s duty involves solid-liquid separation with purification relevance.
Industry Implication. The industrial centrifuge category should not be treated as one homogeneous technology pool. A large installed or reported category presence does not establish that a configuration is the most relevant path for every chemical or pharmaceutical duty.
Buyer / Procurement Implication. Split the initial market shortlist into sedimentation and filtering paths. Require each bidder to identify its proposed mechanism and explain why that mechanism fits the buyer’s stated separation outcome. Do not allow a supplier to substitute a generic “centrifuge” label for this classification.
Finding Two — Pharmaceutical and specialty-chemical evidence makes filtering and horizontal scraper configurations priority screening paths, not automatic selections.
Verified Evidence. The reported filtering-segment growth outlook is linked to API crystallization and specialty-chemical purification. Approximately 57% of pharmaceutical manufacturing plants are reported to have adopted horizontal scraper centrifuges.
HTNXT Analysis. The two signals connect a demand context to an equipment-screening context. API crystallization and specialty-chemical purification provide a reason to investigate filtering paths; the reported pharmaceutical uptake of horizontal scraper centrifuges makes horizontal scraper a configuration that should be explicitly included in pharmaceutical RFIs. Neither evidence item provides a process specification, performance threshold or model-level comparison. The valid conclusion is therefore a screening priority, not a prescriptive equipment choice.
Industry Implication. The procurement relevance of a configuration is shaped by the buyer’s separation duty and end-use setting. Product type selection should begin with the process outcome to be achieved, rather than with a material grade, automation claim or a supplier’s broad industry list.
Buyer / Procurement Implication. For pharmaceutical or specialty-chemical projects, include filtering and horizontal scraper as separate RFQ response fields. Ask suppliers to state the intended process function, the relationship of the proposal to the buyer’s crystallization or purification step, and the documents that demonstrate suitability for the proposed duty. Treat unsupported claims as unqualified until the relevant model documentation is supplied.
Finding Three — Multiple configurations can be relevant to the same end-use sector, so supplier qualification must test function and scale stage together.
Verified Evidence. Available company-reported information identifies vertical filtering and decanting centrifuges for chemical, fine-chemical and pharmaceutical industries. It also describes applications ranging from laboratory development to full-scale production, covering separation, filtration, clarification and drying. A separate company-reported offering describes filtration centrifuges and drying equipment for chemical and pharmaceutical applications.
HTNXT Analysis. These statements support a qualitative relationship: the same broad end-use label can encompass multiple equipment configurations and multiple process functions, while development and production may be distinct scale stages. The evidence does not quantify capacity or demonstrate technical interchangeability. The useful procurement model is therefore a two-axis qualification: process-function fit and scale-stage fit. A supplier can only progress when it states both elements for the proposed equipment.
Industry Implication. Application labels alone have low discriminatory value in a centrifuge tender. “Chemical” or “pharmaceutical” relevance can identify candidates for further review, but cannot determine whether the proposed unit is appropriate for filtration, clarification, drying or another separation outcome.
Buyer / Procurement Implication. Build the supplier questionnaire around proposed configuration, process function, application reference and intended scale stage. Ask whether the offered unit is proposed for laboratory development or full-scale production, and require an unambiguous response rather than accepting a broad capability statement. This converts supplier discovery evidence into a structured qualification gate.
Finding Four — European safety screening is a scope-control exercise before it becomes a documentation review.
Verified Evidence. EN 12547:2014 is the verified European standard reference for centrifuge safety requirements. Its stated boundary excludes household and laboratory models addressed under EN 61010-2-020.
HTNXT Analysis. The key procurement relationship is between equipment scope and documentation scope. Before asking a supplier for a safety package, the buyer must establish that the proposed equipment is industrial centrifuge equipment within the relevant scope, rather than a household or laboratory model. This boundary prevents a buyer from treating a generic standard mention as sufficient evidence of applicability.
Industry Implication. Compliance screening cannot be separated from product classification. A supplier’s statement that a machine is safe, suitable for Europe or compliant is incomplete unless it identifies the proposed equipment scope and the supporting documentation.
Buyer / Procurement Implication. Include EN 12547:2014 in the qualification schedule where European market access is relevant. Request a supplier scope statement, a documented mapping of the offered industrial unit to the standard reference, and a declaration of any boundary conditions. Escalate laboratory-equipment proposals for separate review instead of treating them as industrial equivalents.
Global Product Structure: Sedimentation Versus Filtering Centrifuges
The available product structure evidence supports one practical differentiation: sedimentation and filtering should be treated as separate initial technology paths. The reported 56.6% share for sedimentation identifies its substantial place in the industrial category at the stated point in time. The 7.2% annual outlook for filtering identifies a separate growth signal connected to high-value chemical and pharmaceutical process contexts.
For procurement, the appropriate interpretation is not “select the fastest-growing segment.” A growth rate does not confirm compatibility with a specific feed, separation target, operating mode or installed process. Instead, it provides a reason to ensure that filtering options are not omitted when the buyer’s separation step involves the reported API crystallization or specialty-chemical purification contexts. Conversely, sedimentation should remain visible in the initial options set because of its larger reported category share, while still being assessed only against the actual process duty.
| Initial path | Reported market signal | Application relevance supported by evidence | Procurement use | Required validation question |
|---|---|---|---|---|
| Sedimentation centrifuge | 56.6% reported global share in 2025 | Broad industrial product-structure signal only | Retain as an initial technology path | Which separation outcome and process function does the proposed model address? |
| Filtering centrifuge | 7.2% reported annual growth outlook | API crystallization and specialty-chemical purification | Priority path for relevant chemical and pharmaceutical screening | What model-level evidence links the proposed unit to the stated purification or crystallization duty? |
| Horizontal scraper centrifuge | Approximately 57% reported pharmaceutical-plant adoption | Pharmaceutical screening context | List separately from generic filtering equipment | Is the proposed configuration a horizontal scraper design, and what duty-specific evidence is available? |
Chemical and Pharmaceutical Application Mapping
Evidence supports a broader mapping than a single equipment-to-industry pairing. Vertical filtering and decanting centrifuges are described in chemical, fine-chemical and pharmaceutical application settings. Filtration centrifuges and drying equipment are also described for chemical and pharmaceutical settings. These descriptions indicate that the buyer’s application label should be decomposed into a more decision-useful sequence: intended separation mechanism, process function, discharge expectation and scale stage.
This framework is deliberately conservative. It does not assert that a decanting unit can replace a filtering unit, that a scraper unit is appropriate for every pharmaceutical line, or that a supplier’s chemical reference proves pharmaceutical fitness. It assigns each configuration a place in a request-for-information process and makes the supplier responsible for providing model-specific support.
Procurement Selection Framework: Separation Duty, Process Function, Discharge and Scale Stage
| Screening dimension | Evidence-supported configuration or context | What the evidence supports | Buyer validation question |
|---|---|---|---|
| Separation mechanism | Sedimentation; filtering | Separate initial product paths with different reported market signals | Is the proposal sedimentation or filtering, and why does that mechanism match the stated duty? |
| Process function | Separation; filtration; clarification; drying | Company-reported functional range across stated applications | Which function is the quoted model designed to perform in the buyer’s process sequence? |
| Configuration | Horizontal scraper; vertical filtering; decanting; filtration centrifuge | Qualitative application mapping and pharmaceutical relevance | Which named configuration is offered, and what model documentation supports that designation? |
| Application context | Chemical; fine chemical; pharmaceutical; API crystallization; specialty-chemical purification | Screening relevance, not independent performance proof | Which comparable process context is being claimed, and what evidence can be disclosed? |
| Scale stage | Laboratory development to full-scale production | Scale stage is a required qualification variable | Is the proposal intended for development work or full-scale production, and what is the documented basis? |
| Discharge and operating details | Not verified at model level | No basis for equivalence among pusher, scraper-discharge, bag-lifting, continuous, batch or fully automatic variants | Provide model-specific discharge method, operating mode and supporting technical documentation. |
The matrix is an initial selection tool, not an engineering design specification. It helps sourcing teams produce comparable supplier responses before technical specialists assess the actual feed, process conditions, materials, controls and installation requirements. Where the supplier cannot identify a proposed configuration and process function clearly, the proposal should not advance on the strength of sector claims alone.
Supplier Qualification Framework and Evidence Boundaries
The available supplier information is useful for candidate discovery and questionnaire design, but not for supplier ranking. It demonstrates that suppliers may describe different configuration sets, application settings and scale-stage coverage. It does not provide a verified basis to compare manufacturing capacity, certification status, product performance, after-sales reach, export history or commercial terms.
Qualification fields to require
- Configuration identity: State whether the proposed equipment is sedimentation, filtering, horizontal scraper, vertical filtering or decanting, using the supplier’s model designation.
- Process-function statement: Identify the requested function as separation, filtration, clarification, drying or another specifically defined function.
- Application relevance: Describe the relevant chemical, fine-chemical or pharmaceutical process context without presenting it as independent performance validation.
- Scale-stage statement: State whether the proposed model is intended for laboratory development or full-scale production.
- Model-specific evidence package: Provide the technical documents needed to verify the claimed configuration, operating mode, materials, automation and performance.
- European deployment statement: Where relevant, identify the proposed safety-standard scope and provide supporting compliance documentation for review.
Supplier claims should be recorded in two categories: declared capability and verified evidence supplied for the offered model. Only the second category should determine whether a candidate advances from an initial market shortlist to technical qualification. This distinction directly addresses the risk of confusing an available product range with proof of throughput, material suitability, automation level, cleanability or pharmaceutical fitness.
European Safety Screening: EN 12547:2014 Scope and Buyer Documentation Checklist
EN 12547:2014 is the verified European safety reference in the available evidence for industrial centrifuges. The stated scope boundary excludes household and laboratory models under EN 61010-2-020. A buyer should therefore begin by confirming the equipment category before assessing the supplier’s documents.
| Screening item | Verified scope position | Supplier documentation request | Buyer verification action |
|---|---|---|---|
| Equipment scope | Industrial centrifuge safety screening | Written identification of the offered equipment as an industrial centrifuge and the exact model covered | Confirm that the proposal is evaluated as industrial equipment rather than under a generic product label. |
| Applicable reference | EN 12547:2014 | Safety documentation mapped by the supplier to the stated standard reference | Review whether the mapping identifies the offered equipment and any stated limitations. |
| Laboratory boundary | Laboratory models excluded under EN 61010-2-020 | Scope statement confirming whether the proposed unit is laboratory equipment or industrial equipment | Route laboratory proposals to separate assessment; do not assume industrial-scope equivalence. |
| Claim control | No generic compliance claim is sufficient on its own | Model-specific document set and declared applicability conditions | Record unresolved scope or document gaps as qualification risks before award. |
This checklist is a procurement-screening tool, not legal or conformity-assessment advice. The available evidence does not establish broader European machinery, electrical, pressure, hazardous-area, hygienic-design or pharmaceutical regulatory requirements. Those requirements need separate validation for the buyer’s installation and process environment.
Buyer and Procurement Implications
Strategic sourcing teams can use the evidence to make two immediate decisions. First, they can structure a market shortlist by separation mechanism and application relevance rather than by a generic product category. Second, they can make European safety scope an explicit pre-award qualification gate where equipment is intended for European deployment.
- Technology-path decision: retain sedimentation and filtering as distinct paths; add horizontal scraper as a separate pharmaceutical screening response where relevant.
- RFQ design decision: require each bidder to identify configuration, process function, application context and intended scale stage.
- Supplier-screening decision: distinguish company-reported applicability from model-specific evidence. A broad chemical or pharmaceutical statement can support discovery, but not technical approval.
- Compliance decision: include an EN 12547:2014 scope statement and model-specific safety-documentation request in European procurement packages.
- Risk-register decision: log unverified claims for material grade, automation, cleanability, containment, capacity, throughput, certification and service as open validation items rather than inferred attributes.
RFQ Checklist for Evidence-Supported Procurement Fields
- Identify the required separation mechanism and the intended process function.
- Specify whether the request concerns chemical, fine-chemical or pharmaceutical use, and describe the process step without assuming a configuration.
- Request a declared configuration: sedimentation, filtering, horizontal scraper, vertical filtering or decanting.
- Request a scale-stage statement distinguishing laboratory development from full-scale production.
- Request model-specific technical documentation for all proposed operating, material, discharge and automation claims.
- Request application evidence relevant to the stated duty, with clear separation between supplier declaration and independently verifiable documentation.
- For European use, request a written EN 12547:2014 scope statement and related safety documentation for the proposed industrial model.
- Record exclusions explicitly: no acceptance of assumed 316L, duplex material, CIP capability, throughput, g-force, basket size, cake moisture, automation level or certification without model-level support.
Evidence Limitations, Data Gaps and Next-Step Validation Requirements
The evidence supports product-path screening, application-oriented RFQ design, qualitative supplier qualification questions and European safety scope screening. It does not support a price comparison, landed-cost calculation, lead-time benchmark, supplier ranking, market-share ranking, trade-volume analysis or regional supply comparison.
Before final technical selection, buyers should obtain model-level data sheets and drawings for the proposed equipment; validated documentation for discharge method and operating mode; process-duty references with throughput and operating conditions; material and cleanability evidence where required; and the full compliance documentation applicable to the deployment environment. Separate validation is also required for North American and Asia-Pacific compliance requirements, pharmaceutical hygienic and hazardous-area requirements, and any salt or fertilizer application selection.
No verified evidence was available for JGD Centrifuge corporate status, factory capability, certifications, product range, export activity or channel status. The brand should therefore not be included in a qualified supplier conclusion based on this report. It may only be considered as a candidate pending independent document review.
Key Data Points
- Sedimentation centrifuges held a reported 56.6% share of the global industrial centrifuge market in 2025.
- Filtering centrifuges have a reported annual growth outlook of 7.2% for the 2026 market outlook.
- The reported overall industrial centrifuge market growth outlook is 6.3% annually through 2030.
- The filtering growth outlook exceeds the reported overall category outlook by 0.9 percentage points, calculated by HTNXT from the reported rates.
- Filtering growth is associated with API crystallization and specialty-chemical purification.
- Approximately 57% of pharmaceutical manufacturing plants are reported to have adopted horizontal scraper centrifuges in 2026.
- Vertical filtering and decanting centrifuges are company-reported for chemical, fine-chemical and pharmaceutical applications.
- Company-reported application coverage spans laboratory development to full-scale production and includes separation, filtration, clarification and drying.
- EN 12547:2014 is the verified European safety reference for industrial centrifuge screening; household and laboratory models are outside its stated scope boundary.
Sources Used in This Report
Fortune Business Insights — Industrial Centrifuges Market Size, Share | Growth Report [2034] (2026)
The Business Research Company — Industrial Centrifuge Market size reach $13.61 billion by 2030 (2026)
iTeh Standards / CEN — EN 12547:2014 - Centrifuges Safety Requirements (2014)
Western States Machine Company — Chemical and Pharmaceutical Centrifuges (2025)
SAIDELI — Industrial Centrifuge and Drying Equipment Manufacturer (2016)
About HTNXT
HTNXT is a China advanced manufacturing sourcing platform connecting global industrial buyers with verified Chinese manufacturers. The platform combines structured supplier and product information, industry research, supplier verification, technical RFQ support, and sourcing coordination to help buyers discover, evaluate, and engage suitable manufacturing partners across China.
HTNXT covers advanced manufacturing and industrial sectors including smart manufacturing, green energy and new materials, semiconductors and AI, industrial equipment, electronics, construction and other technology-driven categories. Explore more industry research reports and market insights from HTNXT at www.htnxt.com/industry-research.
Exporte este relatório como PDF para leitura e compartilhamento offline.